Related Experiment Video
Updated: May 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study
Giordano Madeddu1, Barbara Menzaghi, Elena Ricci
1Department of Clinical and Experimental Medicine, University of Sassari, Italy. giordano.madeddu@uniss.it
Abstract:
Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Therapeutic Drug Monitoring: Affecting Factors
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Clinical Trials: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
